Precision Oncology Flourishes In-House
The UK is headed toward test centralization – but the value of in-house testing must not be underestimated
Tanya Ahmad | | Interview
sponsored by Thermo Fisher Scientific
The UK’s 100,000 Genomes Project reached its goal of sequencing 100,000 entire patient genomes in December 2018. Capitalizing on this success, January 2019 saw the establishment of a new, nationally commissioned Genomic Medicine Service that harnesses seven Genomic Laboratory Hubs around the country. The goal is to standardize the criteria for whole genome sequencing and targeted panel tests, simplifying patient pathways and reducing social inequalities – but is this democratization of genetic testing the best option for all institutions? We spoke to Tanya Ahmad, Consultant Medical Oncologist in London, to discover her personal outlook on in-house testing versus centralization.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.